Moving at the Speed of Oncology: Lunch & Learn
Charles River Event
In the fast-paced field of oncology research, it can be tough to stay up to date on the latest advancements. Charles River Discovery offers a comprehensive, integrated oncology portfolio with proven expertise to support drug development from hit ID to IND. Selecting the most appropriate model to advance your research can be a challenging step. Charles River has guided clients to success with a record of more than 60 patents and 16 clinical candidates, and work on 88% of oncology therapies approved in 2018.
We are proud to have played a role in bringing life-saving treatments to cancer patients.
Patients are waiting for safe, effective cancer therapies, but oncology drug discovery is highly complex, demanding a strategic approach to identify promising compounds then optiize lead candidates. During this lunch and learn event, learn how to select the right models for your research, and combine these with appropriate biomarkers (e.g., flow cytometry, imaging and more), to establish the optimum study design and screening method for your program.
- Paula Miliani de Marval, PhD: Oncology Program Strategies: Lessons Learned from Newly Emergent Humanized Mouse Models for Immuno-Oncology
- Christopher L. Murriel, PhD: Beyond Antibodies and Small Molecules: Thinking Outside the Box with Preclinical Development Strategies